Global Smith-Magenis Syndrome Drug Market, By Drug Class (Anti-Convulsants, B-Blockers, Melanin Supplements, Others), Drugs (Trazodone, Acebutolol, Risperdal, Others), Diagnosis (G-Band Analysis, Chromosomal Microarray Analysis, Molecular Genetic Testing), Therapy (Physical Therapy, Occupational Therapy and Speech Therapy, Sensory Integration Therapy), Treatment (Medication, Supportive Care), Route of Administration (Oral, Parenteral), End Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Direct, Online Pharmacy, Retailers, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028